Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results
Backbone: Paclitaxel and docetaxel are the primary taxane anticancer drugs regularly used to treat, breast, gastric, ovarian, head/neck, lung, and genitourinary neoplasm. Suspension of taxane treatments compromising patient benefits is more frequently caused by peripheral neuropathy and allergy, tha...
Main Authors: | Raffaele Di Francia, Luigi Atripaldi, Salvo Di Martino, Carla Fierro, Tommaso Muto, Anna Crispo, Sabrina Rossetti, Gaetano Facchini, Massimiliano Berretta |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2017.00797/full |
Similar Items
-
Validation of a simple genotyping panel assay for pharmacogenomics of taxane-based therapy: preliminary results
by: A. Vitale, et al.
Published: (2023-12-01) -
Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites
by: Margarida L. F. Martins, et al.
Published: (2022-03-01) -
Pharmacokinetics and Pharmacogenetics of Apixaban
by: A. V. Savinova, et al.
Published: (2020-11-01) -
CLOPIDOGREL PHARMACOGENETICS
by: A. N. Meshkov
Published: (2016-01-01) -
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
by: Ingrid Fricke-Galindo, et al.
Published: (2021-03-01)